AP200302734A0 - Purification of 1bv antigens for use in vaccines - Google Patents

Purification of 1bv antigens for use in vaccines

Info

Publication number
AP200302734A0
AP200302734A0 AP200302734A AP200302734A AP200302734A0 AP 200302734 A0 AP200302734 A0 AP 200302734A0 AP 200302734 A AP200302734 A AP 200302734A AP 200302734 A AP200302734 A AP 200302734A AP 200302734 A0 AP200302734 A0 AP 200302734A0
Authority
AP
ARIPO
Prior art keywords
1bv
vaccines
antigens
purification
use
Prior art date
Application number
AP200302734A
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB0019728.5A priority Critical patent/GB0019728D0/en
Priority to GB0101334A priority patent/GB0101334D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority to PCT/EP2001/009100 priority patent/WO2002012287A1/en
Publication of AP200302734A0 publication Critical patent/AP200302734A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/463The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV]
    • Y02A50/464The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV] the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/465The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio
    • Y02A50/466The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
AP200302734A 2000-08-10 2001-08-07 Purification of 1bv antigens for use in vaccines AP200302734A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds
PCT/EP2001/009100 WO2002012287A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines

Publications (1)

Publication Number Publication Date
AP200302734A0 true AP200302734A0 (en) 2003-03-31

Family

ID=26244821

Family Applications (1)

Application Number Title Priority Date Filing Date
AP200302734A AP200302734A0 (en) 2000-08-10 2001-08-07 Purification of 1bv antigens for use in vaccines

Country Status (36)

Country Link
US (3) US20030235590A1 (en)
EP (2) EP1307473B1 (en)
JP (2) JP2004505992A (en)
KR (1) KR100804922B1 (en)
CN (1) CN1468256B (en)
AP (1) AP200302734A0 (en)
AR (1) AR030325A1 (en)
AT (2) AT412665T (en)
AU (2) AU2001282073B2 (en)
BG (1) BG66038B1 (en)
BR (2) BR0113155A (en)
CA (2) CA2740282A1 (en)
CY (1) CY1108789T1 (en)
CZ (1) CZ303217B6 (en)
DE (2) DE60116107T2 (en)
DK (2) DK1307473T3 (en)
DZ (1) DZ3470A1 (en)
EA (1) EA006433B1 (en)
EG (1) EG25829A (en)
ES (2) ES2254464T3 (en)
HK (1) HK1056884A1 (en)
HU (1) HU228932B1 (en)
IL (2) IL154301D0 (en)
MX (1) MXPA03001235A (en)
MY (1) MY128999A (en)
NO (1) NO20030635L (en)
NZ (1) NZ524012A (en)
OA (1) OA12361A (en)
PE (1) PE20020287A1 (en)
PL (1) PL204736B1 (en)
PT (1) PT1666487E (en)
SI (2) SI1307473T1 (en)
SK (2) SK288079B6 (en)
UA (1) UA79735C2 (en)
UY (1) UY26882A1 (en)
WO (1) WO2002012287A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1468256B (en) * 2000-08-10 2010-10-27 史密丝克莱恩比彻姆生物有限公司 Purification of HBV antigens for use in vaccines
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
CN101262883A (en) * 2005-07-11 2008-09-10 环球免疫公司 Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
WO2007015167A2 (en) * 2005-08-02 2007-02-08 Novartis Vaccines And Diagnostics Srl Reducing interference between oil-containing adjuvants and surfactant-containing antigens
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
NZ575272A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Inactivated poliovirus type 1, diptheria toxoid, tetanus toxoid and killed whole-cell Bordetella pertussis vaccine
CA2685506A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (en) 2008-03-21 2010-05-25 중앙대학교 산학협력단 Process for Producing and Purifying Human Papillomavirus Virus-Like Particles
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
SG176220A1 (en) * 2009-05-27 2011-12-29 Glaxosmithkline Biolog Sa Casb7439 constructs
PT2705365T (en) * 2011-01-14 2016-09-19 Hal Allergy Holding B V Immunoassay for direct determination of antigen content of products comprising adjuvant-coupled-antigen particles
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (en) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 A kind of cell culture medium improving antibody purity and cultural method
WO2019016654A1 (en) 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPH0437806B2 (en) 1983-07-05 1992-06-22 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
KR850001534A (en) 1983-08-22 1985-03-30 제임스 에프. 나우톤 Trait derived from the yeast transition immunogenic HBsAg
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis B ytantigen framstaelld with a recombinant DNA technician, vaccinia, test kit agents, and cellinjer samt foerfaranden Foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA8800488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (en) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 A-type and b-type hepatitis mixed adjuvant vaccine
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
CN1176658A (en) * 1994-10-24 1998-03-18 蛇药制品有限公司 Vaccine and antitoxin for treatment and prevention of C. difficile disease
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
JP3026029B2 (en) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 The recombinant varicella virus and its production method
EP0533492A3 (en) 1991-09-18 1994-08-10 Amgen Inc A hepatitis b vaccine formulation incorporating a bile acid salt
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
KR0177254B1 (en) * 1994-12-10 1999-04-01 Lg Chemical Ltd
CA2217178C (en) 1995-04-25 2009-09-29 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
ES2273482T3 (en) * 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Compositions of combined vaccines.
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000037104A1 (en) * 1998-12-23 2000-06-29 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
CN1468256B (en) * 2000-08-10 2010-10-27 史密丝克莱恩比彻姆生物有限公司 Purification of HBV antigens for use in vaccines

Also Published As

Publication number Publication date
EA200300129A1 (en) 2003-10-30
EP1307473B1 (en) 2005-12-21
MY128999A (en) 2007-03-30
OA12361A (en) 2004-04-13
US20060159705A1 (en) 2006-07-20
AR030325A1 (en) 2003-08-20
SI1666487T1 (en) 2009-02-28
PL204736B1 (en) 2010-02-26
EA006433B1 (en) 2005-12-29
AT412665T (en) 2008-11-15
PE20020287A1 (en) 2002-06-20
US8624004B2 (en) 2014-01-07
AT313558T (en) 2006-01-15
DE60116107T2 (en) 2006-08-03
KR20030029127A (en) 2003-04-11
SK1692003A3 (en) 2003-08-05
NZ524012A (en) 2004-02-27
KR100804922B1 (en) 2008-02-20
BRPI0113155B1 (en) 2018-11-21
JP2012255015A (en) 2012-12-27
JP5559847B2 (en) 2014-07-23
ES2314555T3 (en) 2009-03-16
SK288079B6 (en) 2013-06-03
IL154301A (en) 2009-11-18
DE60136400D1 (en) 2008-12-11
HU0302951A3 (en) 2004-10-28
SK288069B6 (en) 2013-05-03
CZ2003385A3 (en) 2003-06-18
PT1666487E (en) 2008-12-26
ES2254464T3 (en) 2006-06-16
CY1108789T1 (en) 2014-04-09
CN1468256A (en) 2004-01-14
BG107545A (en) 2004-01-30
UY26882A1 (en) 2002-03-22
DE60116107D1 (en) 2006-01-26
DK1307473T3 (en) 2006-05-01
IL154301D0 (en) 2003-09-17
HK1056884A1 (en) 2006-08-25
CA2740282A1 (en) 2002-02-11
BRPI0113155B8 (en) 2019-08-13
EG25829A (en) 2012-09-02
DZ3470A1 (en) 2002-02-14
AU2001282073B2 (en) 2005-01-20
BG66038B1 (en) 2010-11-30
HU228932B1 (en) 2013-06-28
US20090123496A1 (en) 2009-05-14
WO2002012287A1 (en) 2002-02-14
BR0113155A (en) 2003-07-08
MXPA03001235A (en) 2004-07-16
AU8207301A (en) 2002-02-18
CA2427475C (en) 2011-07-05
NO20030635D0 (en) 2003-02-07
DK1666487T3 (en) 2009-01-12
JP2004505992A (en) 2004-02-26
EP1666487B1 (en) 2008-10-29
EP1307473A1 (en) 2003-05-07
CA2427475A1 (en) 2002-02-11
SI1307473T1 (en) 2006-04-30
US20030235590A1 (en) 2003-12-25
HU0302951A2 (en) 2003-12-29
EP1666487A1 (en) 2006-06-07
PL362322A1 (en) 2004-10-18
UA79735C2 (en) 2007-07-25
CZ303217B6 (en) 2012-05-30
CN1468256B (en) 2010-10-27
NO20030635L (en) 2003-04-01

Similar Documents

Publication Publication Date Title
DE60142689D1 (en) Use of procariotic pest-similar peptides for increasing the immunogenicity of antigens
DE50211324D1 (en) Process for preparing polyurethanelastomers and use
DK1163000T3 (en) Vaccines against bacteria antigens
DK1261377T3 (en) Immunomodulatory formulations and methods for their use
DK1276472T3 (en) Formulations for use in inhaler devices
GB2397770B (en) Disposable absorbent article
DE60234375D1 (en) PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
DE69928763D1 (en) Adjuvants for use in vaccines
DE60131430D1 (en) Oligode oxynucleotides and their use for inducing an immune reaction
SG101520A1 (en) Disposable undergarment
AU3528401A (en) Methods and compositions for improving sleep
AU6135401A (en) Cordierite body
AU1695502A (en) Polyfunctional organosilane for use as coupling agent and method for obtaining same
AU9650701A (en) Human anti-cd40 antibodies
HK1040517A1 (en) Novel aralkyl amines of spirofuropyridines useful in therapy
EP1543039A4 (en) Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
AU8345001A (en) Adjustable holding device and methods of using same
SG94777A1 (en) Absorbent article
SG97217A1 (en) Absorbent article
SG100739A1 (en) Absorbent article
TW524101U (en) Shorts-pant type disposable article
HU0301697A3 (en) Oral solid dose vaccine
AU6447101A (en) Absorbent article
AU3614801A (en) Polyorganosilsesquioxane and process for preparing the same
AU5299501A (en) Disposable absorbent article having releasable and reattachable positioning flaps